A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Hoosier Cancer Research Network
AstraZeneca
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
AstraZeneca
Dana-Farber Cancer Institute
AHS Cancer Control Alberta
The University of Hong Kong
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)